Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Status Complete
Process MTA
Topic area
  • Musculoskeletal


Key events during the development of the guidance:

Date Update
26 January 2016 Appeal
26 January 2016 Guidance published
26 January 2016 Appeal decision
20 April 2015 In line with NICE’s position statement on biosimilarstwo additional technologies have been included in the scope and matrix for this appraisal. The technologies are biosimilar productsfor infliximab, both have marketing authorisation approvals and are launched in the UK. They are Napp pharmaceuticals infliximab (Remsima) and Hospira UKs infliximab (Inflectra).
17 December 2014 Following a stakeholder information meeting in December 2014, the February 2015 meeting has been rescheduled to May 2015. This is to allow consultation on the DSU report and the addendum to the assessment report before the Appraisal Committee meets in May 2015.
13 August 2014 Following the consultation with consultees and commentators on the executable economic model for this appraisal NICE agreed that further work on HAQ progression was required. The Decision SupportUnit (DSU) has been commissioned to take on this additional work. Once this work is complete NICE will look to arrange the next Committee meeting for this topic in February 2015.
11 December 2013 Consultees and commentators are invited to consult on the executable economic model for this appraisal topic until 5pm Wednesday 22 January 2014. Comments received from consultees and commentators on the model will be considered by the Committee at the next Appraisal Committee meeting which, the date of which is still to be confirmed.
07 November 2013 The current scheduled second Committee meeting on 07 January 2014 for this appraisal topic has been cancelled.This is to allow NICE to work towards releasing an executable model for consultee and commentator comment and an external review of the evidence for disease progression in rheumatoid arthritis prior to the Committee meeting to finalise its preliminary recommendations.
07 May 2013 To allow adequate preparation time for the assessment report and economic model in advance of consultation, the appraisal committee meeting dates for this appraisal have been rescheduled.
21 February 2013 The British Society of Rheumatologists submitted comments on the draft scope and provisional matrix that were identified, in error, after the invitation to participate was sent to consultees and commentators. NICE apologises for this error. A replacement comments table, including the BSR comments is available to view under key documents.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance